144 related articles for article (PubMed ID: 25153390)
21. miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.
Ray J; Haughey C; Hoey C; Jeon J; Murphy R; Dura-Perez L; McCabe N; Downes M; Jain S; Boutros PC; Mills IG; Liu SK
Cancer Lett; 2020 Mar; 473():107-117. PubMed ID: 31874245
[TBL] [Abstract][Full Text] [Related]
22. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
23. miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer.
Chen R; Sheng L; Zhang HJ; Ji M; Qian WQ
J Cell Mol Med; 2018 Mar; 22(3):1855-1863. PubMed ID: 29363862
[TBL] [Abstract][Full Text] [Related]
24. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
25. miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment.
Qu Y; Huang X; Li Z; Liu J; Wu J; Chen D; Zhao F; Mu D
Am J Pathol; 2014 May; 184(5):1541-9. PubMed ID: 24631181
[TBL] [Abstract][Full Text] [Related]
26. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.
Fendler A; Jung M; Stephan C; Honey RJ; Stewart RJ; Pace KT; Erbersdobler A; Samaan S; Jung K; Yousef GM
Int J Oncol; 2011 Nov; 39(5):1183-92. PubMed ID: 21769427
[TBL] [Abstract][Full Text] [Related]
27. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy.
Casanova-Salas I; Rubio-Briones J; Calatrava A; Mancarella C; Masiá E; Casanova J; Fernández-Serra A; Rubio L; Ramírez-Backhaus M; Armiñán A; Domínguez-Escrig J; Martínez F; García-Casado Z; Scotlandi K; Vicent MJ; López-Guerrero JA
J Urol; 2014 Jul; 192(1):252-9. PubMed ID: 24518785
[TBL] [Abstract][Full Text] [Related]
28. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
[TBL] [Abstract][Full Text] [Related]
29. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy.
Compérat E; Rouprêt M; Drouin SJ; Camparo P; Bitker MO; Houlgatte A; Cancel-Tassin G; Cussenot O
Prostate; 2010 Nov; 70(15):1622-7. PubMed ID: 20687232
[TBL] [Abstract][Full Text] [Related]
30. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.
White NM; Youssef YM; Fendler A; Stephan C; Jung K; Yousef GM
Biol Chem; 2012 Apr; 393(5):379-89. PubMed ID: 22505520
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
[TBL] [Abstract][Full Text] [Related]
32. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
[TBL] [Abstract][Full Text] [Related]
33. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
34. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
35. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.
Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer.
Matin F; Jeet V; Srinivasan S; Cristino AS; Panchadsaram J; Clements JA; Batra J;
Clin Chem; 2019 Jun; 65(6):771-780. PubMed ID: 31018918
[TBL] [Abstract][Full Text] [Related]
37. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
39. Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer.
Ohara S; Oue N; Matsubara A; Mita K; Hasegawa Y; Hayashi T; Usui T; Amatya VJ; Takeshima Y; Kuniyasu H; Yasui W
Cancer Sci; 2008 Aug; 99(8):1570-7. PubMed ID: 18754868
[TBL] [Abstract][Full Text] [Related]
40. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
